These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 36959420)

  • 1. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy.
    Bärthel S; Falcomatà C; Rad R; Theis FJ; Saur D
    Nat Cancer; 2023 Apr; 4(4):454-467. PubMed ID: 36959420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma.
    Evan T; Wang VM; Behrens A
    Oncogene; 2022 Oct; 41(42):4686-4695. PubMed ID: 36088504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling pancreatic cancer in mice for experimental therapeutics.
    Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell sequencing in pancreatic cancer research: A deeper understanding of heterogeneity and therapy.
    Liu Z; Zhang Y; Wu C
    Biomed Pharmacother; 2023 Dec; 168():115664. PubMed ID: 37837881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer stem cells: A state or an entity?
    Hermann PC; Sainz B
    Semin Cancer Biol; 2018 Dec; 53():223-231. PubMed ID: 30130664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated study to decipher immunosuppressive cellular communication in the PDAC environment.
    Avşar G; Pir P
    NPJ Syst Biol Appl; 2023 Nov; 9(1):56. PubMed ID: 37945567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    Environ Toxicol; 2024 Feb; 39(2):572-582. PubMed ID: 37449672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of PDAC subtype heterogeneity and therapy response.
    Espinet E; Klein L; Puré E; Singh SK
    Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
    Hidalgo M; Von Hoff DD
    Clin Cancer Res; 2012 Aug; 18(16):4249-56. PubMed ID: 22896691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
    Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
    Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.